The combined company is expected to have a diversified revenue base from 12 products currently marketed in the US in the CNS and women’s health areas.
Following the merger, shareholders of Jazz would own slightly under 80% of Jazz Pharmaceuticals plc, and Azur Pharma shareholders would own slightly over 20%.
Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, would be chairman and CEO of Jazz Pharmaceuticals plc.
Jazz chairman and CEO Bruce Cozadd said their combined organizations would have a diverse portfolio of products and an international platform, paving the way for long term growth that builds on their current strengths.